Results 91 to 100 of about 290 (122)

Nootropic Dipeptide Noopept Enhances Inhibitory Synaptic Transmission in the Hippocampus

Bulletin of Experimental Biology and Medicine, 2015
Application of nootropic agent Noopept on hippocampal slices from Wistar rats enhanced the inhibitory component of total current induced by stimulation of Shaffer collaterals in CA1 pyramidal neurons, but did not affect the excitatory component. A direct correlation between the increase in the amplitude of inhibitory current and agent concentration was
I S, Povarov, R V, Kondratenko, V I, Derevyagin, R U, Ostrovskaya, V G, Skrebitskii   +4 more
openaire   +2 more sources

[The original novel nootropic and neuroprotective agent noopept].

Eksperimental'naia i klinicheskaia farmakologiia, 2003
The paper describes pharmacological properties of the new nootropic drug noopept created using an original approach based on the imitation of a nonpeptide nootrope structure by means of the short-peptide design. In particular, the structure of pyracetam was designed using dipeptide nootropes.
R U, Ostrovskaia, T A, Gudasheva, T A, Voronina, S B, Seredenin   +3 more
openaire   +2 more sources

Neuroprotective Dipeptide Noopept Prevents DNA Damage in Mice with Modeled Prediabetes

Bulletin of Experimental Biology and Medicine, 2019
In experiments on BALB/c mice, prediabetes was modeled by administration of streptozotocin in a dose of 130 mg/kg. DNA damage was assessed by the method of DNA comets. Noopept (0.5 mg/kg intraperitoneally) was administered for 14 days before and for 6, 13, or 14 days after streptozotocin administration.
R U, Ostrovskaya, S S, Yagubova, A K, Zhanataev, E A, Anisina, T A, Gudasheva, A D, Durnev   +5 more
openaire   +2 more sources

Drug with Neuroprotective Properties Noopept Does Not Stimulate Cell Proliferation

Bulletin of Experimental Biology and Medicine, 2019
Effects of Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) on the relative level of proliferation marker Ki-67 and cell cycle parameters were studied in HEK293 and SH-SY5Y cell lines. The previously established multifactorial mechanism of action of the drug includes enhancement of neurotrophin NGF and BDNF expression and increase in HIF-1 activity.
L F, Zainullina, T V, Ivanova, R U, Ostrovskaya, T A, Gudasheva, Yu V, Vakhitova, S B, Seredenin   +5 more
openaire   +2 more sources

Neuroprotective and Nootropic Drug Noopept Rescues α-Synuclein Amyloid Cytotoxicity

Journal of Molecular Biology, 2011
Parkinson's disease is a common neurodegenerative disorder characterized by α-synuclein (α-Syn)-containing Lewy body formation and selective loss of dopaminergic neurons in the substantia nigra. We have demonstrated the modulating effect of noopept, a novel proline-containing dipeptide drug with nootropic and neuroprotective properties, on α-Syn ...
Xueen, Jia, Anna L, Gharibyan, Anders, Öhman, Yonggang, Liu, Anders, Olofsson, Ludmilla A, Morozova-Roche   +5 more
openaire   +2 more sources

Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats

Biomeditsinskaya Khimiya, 2018
The study of the pharmacokinetics of new drugs and the identification of active metabolites is a necessary step for effective and safe use in the clinical practice. It is especially important for peptide drugs due to their enzymatic instability, low bioavailability and poor permeability through the blood-brain barrier (BBB).
S S, Boyko, V P, Zherdev, R V, Shevchenko   +2 more
openaire   +2 more sources

Noopept Normalizes Parameters of the Incretin System in Rats with Experimental Diabetes

Bulletin of Experimental Biology and Medicine, 2014
Experiments on adult Wistar rats with streptozotocin-induced diabetes showed that antihyperglycemic activity of an original nootropic and neuroprotective drug Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is more pronounced under conditions of oral application than after intraperitoneal injection.
R U, Ostrovskaya, N N, Zolotov, I V, Ozerova, E A, Ivanova, I G, Kapitsa, K V, Taraban, A M, Michunskaya, T A, Voronina, T A, Gudasheva, S B, Seredenin   +9 more
openaire   +2 more sources

[Interspecies differences of noopept pharmacokinetics].

Eksperimental'naia i klinicheskaia farmakologiia, 2004
Significant interspecific differences in the pharmacokinetics of noopept are manifested by a decrease in the drug elimination rate on the passage from rats to rabbits and humans. Very intensive metabolism of noopept was observed upon intravenous administration in rats.
S S, Boĭko, S A, Korotkov, V P, Zherdev, T A, Gudasheva, R U, Ostrovskaia, T A, Voronina   +5 more
openaire   +1 more source

Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells

Neuroscience Letters, 2010
Effects of newly synthesized nootropic and anxiolytic dipeptide Noopept on inhibitory synaptic transmission in hippocampal CA1 pyramidal cells were investigated using patch-clamp technique in whole-cell configuration. Bath application of Noopept (1 microM) significantly increased the frequency of spike-dependant spontaneous IPSCs whereas spike ...
Rodion V, Kondratenko, Vladimir I, Derevyagin, Vladimir G, Skrebitsky   +2 more
openaire   +2 more sources

[Preclinical study of noopept toxicity].

Eksperimental'naia i klinicheskaia farmakologiia, 2002
Within the framework of a preclinical investigation, the new nootrope drug noopept (N-phenyl-acetyl-L-propyl-glycine ethylate) was tested for chronic toxicity upon peroral administration in a dose of 10 or 100 mg/kg over 6 months in both male and female rabbits.
L P, Kovalenko, N M, Smol'nikova, S V, Alekseeva, E P, Nemova, A V, Sorokina, M G, Miramedova, S P, Kurapova, E I, Sidorina, A V, Kulakova, N O, Daugel'-Dauge   +9 more
openaire   +1 more source